Please login to the form below

Not currently logged in
Email:
Password:

Hepatitis B virus

This page shows the latest Hepatitis B virus news and features for those working in and with pharma, biotech and healthcare.

Ionis must go it alone as GSK ditches polyneuropathy drug

Ionis must go it alone as GSK ditches polyneuropathy drug

GSK isn't giving up on Ionis’pipeline entirely, however. The pharma group is still developing two Ionis drugs for hepatitis B virus in phase II trials.

Latest news

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    The European Commission has granted Gilead's Vemlidy European marketing authorisation, making it the first new hepatitis B virus (HBV) treatment to receive EU approval in nearly a decade. ... infectious diseases, including hepatitis B, while we continue

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    Gilead's hepatitis B virus treatment set for European approval. CHMP also recommends diabetes drugs from Sanofi and Novo Nordisk. ... Gilead Sciences' once-daily chronic hepatitis B virus (HBV) therapy Vemlidy has been recommended for the treatment of

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    A new combination therapy for hepatitis C virus (HCV) from Gilead Sciences could be approved in the US by the summer after being awarded a priority review by the FDA. ... Meanwhile, Gilead has also reported positive news in the area of hepatitis B virus

  • J&J buys firm seeking hepatitis B cure J&J buys firm seeking hepatitis B cure

    J&J buys firm seeking hepatitis B cure. Acquires Philadelphia-based Novira therapeutics. ... Johnson &Johnson (J&J) has agreed to buy a Pennsylvania biotech company that is trying to develop treatments to cure hepatitis B virus (HBV) infection.

  • Mylan to sell Gilead's medicines in India Mylan to sell Gilead's medicines in India

    Mylan can also sell Viread in its other indication as a treatment for chronic hepatitis B virus. ... Stribild's simple regimen is down to its combination of elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil, each of which works in a

More from news
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. ... These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics